secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2026-06-12T20:05:21+00:00
Accession:  0001104659-26-073419
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Pharma annual meeting elects director; proxy share count corrected
---------------------------------------------------------------------------

- Proxy mistakenly stated 27,668,036 shares outstanding; correct count is 26,614,628.
- Quorum of 60.8% (16,193,686 shares) present at June 11, 2026 annual meeting.
- Ron Bentsur elected Class I director with 8,354,838 votes for, 391,265 against.
- Kesselman & Kesselman ratified as independent auditor for FY2026 (15,662,222 for).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465926073419/0001104659-26-073419-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465926073419/tm2617533d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-073419

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer